Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Carboplatin
Related studies linked through entity extraction aliases.
A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)
- Status
- COMPLETED
- Phase
- PHASE3
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
- Status
- WITHDRAWN
- Phase
- PHASE2
IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery
- Status
- TERMINATED
- Phase
- PHASE2
Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Paediatric Hepatic International Tumour Trial
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)
- Status
- COMPLETED
- Phase
- PHASE3
Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies
- Status
- TERMINATED
- Phase
- PHASE2
Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
- Status
- TERMINATED
- Phase
- PHASE2
Neoadjuvant Carboplatin in Triple Negative Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001)
- Status
- COMPLETED
- Phase
- PHASE1
Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
The BARCODE 2 Study - The Use of Genetic Profiling to Guide Prostate Cancer Treatment
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2